Lipocine inc. announces first biopsy confirmed nash patient dosed in lipocine lift study of lpcn 1144

Lipocine inc. announced that the first patient has been dosed in its lift (“liver fat intervention with oral testosterone”) phase 2 clinical study, a paired-biopsy study in confirmed pre-cirrhotic non-alcoholic steatohepatitis (“nash”) subjects. the lift phase 2 clinical study is a prospective, multi-center, randomized, double-blind, placebo-controlled multiple-arm study in biopsy-confirmed male nash subjects with grade f2/f3 fibrosis and a nafld activity score (“nas”) = 4 with a 36-week treatment period. the lift clinical study is designed to enroll approximately 75 biopsy confirmed nash male subjects, randomized into one of three arms (two test arms and one placebo arm) with a 1:1:1 randomization ratio.
LPCN Ratings Summary
LPCN Quant Ranking